Cargando…
Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease
The development of pharmacological therapies for mitochondrial diseases is hampered by the lack of tissue‐level and circulating biomarkers reflecting effects of compounds on endothelial and mitochondrial function. This phase 0 study aimed to identify biomarkers differentiating between patients with...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339694/ https://www.ncbi.nlm.nih.gov/pubmed/37177864 http://dx.doi.org/10.1111/cts.13530 |
_version_ | 1785071902848450560 |
---|---|
author | van Kraaij, Sebastiaan J. W. Pereira, Diana R. Smal, Bastiaan Summo, Luciana Konkel, Anne Lossie, Janine Busjahn, Andreas Grammatopoulos, Tom N. Klaassen, Erica Fischer, Robert Schunck, Wolf‐Hagen Gal, Pim Moerland, Matthijs |
author_facet | van Kraaij, Sebastiaan J. W. Pereira, Diana R. Smal, Bastiaan Summo, Luciana Konkel, Anne Lossie, Janine Busjahn, Andreas Grammatopoulos, Tom N. Klaassen, Erica Fischer, Robert Schunck, Wolf‐Hagen Gal, Pim Moerland, Matthijs |
author_sort | van Kraaij, Sebastiaan J. W. |
collection | PubMed |
description | The development of pharmacological therapies for mitochondrial diseases is hampered by the lack of tissue‐level and circulating biomarkers reflecting effects of compounds on endothelial and mitochondrial function. This phase 0 study aimed to identify biomarkers differentiating between patients with mitochondrial disease and healthy volunteers (HVs). In this cross‐sectional case–control study, eight participants with mitochondrial disease and eight HVs matched on age, sex, and body mass index underwent study assessments consisting of blood collection for evaluation of plasma and serum biomarkers, mitochondrial function in peripheral blood mononuclear cells (PBMCs), and an array of imaging methods for assessment of (micro)circulation. Plasma biomarkers GDF‐15, IL‐6, NT‐proBNP, and cTNI were significantly elevated in patients compared to HVs, as were several clinical chemistry and hematology markers. No differences between groups were found for mitochondrial membrane potential, mitochondrial reactive oxygen production, oxygen consumption rate, or extracellular acidification rate in PBMCs. Imaging revealed significantly higher nicotinamide‐adenine‐dinucleotide‐hydrogen (NADH) content in skin as well as reduced passive leg movement‐induced hyperemia in patients. This study confirmed results of earlier studies regarding plasma biomarkers in mitochondrial disease and identified several imaging techniques that could detect functional differences at the tissue level between participants with mitochondrial disease and HVs. However, assays of mitochondrial function in PBMCs did not show differences between participants with mitochondrial disease and HVs, possibly reflecting compensatory mechanisms and heterogeneity in mutational load. In future clinical trials, using a mix of imaging and blood‐based biomarkers may be advisable, as well as combining these with an in vivo challenge to disturb homeostasis. |
format | Online Article Text |
id | pubmed-10339694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103396942023-07-14 Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease van Kraaij, Sebastiaan J. W. Pereira, Diana R. Smal, Bastiaan Summo, Luciana Konkel, Anne Lossie, Janine Busjahn, Andreas Grammatopoulos, Tom N. Klaassen, Erica Fischer, Robert Schunck, Wolf‐Hagen Gal, Pim Moerland, Matthijs Clin Transl Sci Research The development of pharmacological therapies for mitochondrial diseases is hampered by the lack of tissue‐level and circulating biomarkers reflecting effects of compounds on endothelial and mitochondrial function. This phase 0 study aimed to identify biomarkers differentiating between patients with mitochondrial disease and healthy volunteers (HVs). In this cross‐sectional case–control study, eight participants with mitochondrial disease and eight HVs matched on age, sex, and body mass index underwent study assessments consisting of blood collection for evaluation of plasma and serum biomarkers, mitochondrial function in peripheral blood mononuclear cells (PBMCs), and an array of imaging methods for assessment of (micro)circulation. Plasma biomarkers GDF‐15, IL‐6, NT‐proBNP, and cTNI were significantly elevated in patients compared to HVs, as were several clinical chemistry and hematology markers. No differences between groups were found for mitochondrial membrane potential, mitochondrial reactive oxygen production, oxygen consumption rate, or extracellular acidification rate in PBMCs. Imaging revealed significantly higher nicotinamide‐adenine‐dinucleotide‐hydrogen (NADH) content in skin as well as reduced passive leg movement‐induced hyperemia in patients. This study confirmed results of earlier studies regarding plasma biomarkers in mitochondrial disease and identified several imaging techniques that could detect functional differences at the tissue level between participants with mitochondrial disease and HVs. However, assays of mitochondrial function in PBMCs did not show differences between participants with mitochondrial disease and HVs, possibly reflecting compensatory mechanisms and heterogeneity in mutational load. In future clinical trials, using a mix of imaging and blood‐based biomarkers may be advisable, as well as combining these with an in vivo challenge to disturb homeostasis. John Wiley and Sons Inc. 2023-05-12 /pmc/articles/PMC10339694/ /pubmed/37177864 http://dx.doi.org/10.1111/cts.13530 Text en © 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research van Kraaij, Sebastiaan J. W. Pereira, Diana R. Smal, Bastiaan Summo, Luciana Konkel, Anne Lossie, Janine Busjahn, Andreas Grammatopoulos, Tom N. Klaassen, Erica Fischer, Robert Schunck, Wolf‐Hagen Gal, Pim Moerland, Matthijs Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease |
title | Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease |
title_full | Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease |
title_fullStr | Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease |
title_full_unstemmed | Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease |
title_short | Identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease |
title_sort | identification of peripheral vascular function measures and circulating biomarkers of mitochondrial function in patients with mitochondrial disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339694/ https://www.ncbi.nlm.nih.gov/pubmed/37177864 http://dx.doi.org/10.1111/cts.13530 |
work_keys_str_mv | AT vankraaijsebastiaanjw identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT pereiradianar identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT smalbastiaan identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT summoluciana identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT konkelanne identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT lossiejanine identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT busjahnandreas identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT grammatopoulostomn identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT klaassenerica identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT fischerrobert identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT schunckwolfhagen identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT galpim identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease AT moerlandmatthijs identificationofperipheralvascularfunctionmeasuresandcirculatingbiomarkersofmitochondrialfunctioninpatientswithmitochondrialdisease |